Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Informa H1 revenues grow, upgrades FY guidance

(Sharecast News) - Publishing and exhibitions group Informa said on Wednesday that H1 revenue growth and strong forward visibility had led it to upgrade FY guidance. Informa said reported revenues had grown by 20.1% in the six months ended 30 June, while adjusted operating profits increased 24% to £578.9m and earnings per share rose by 25.2% to 29.8p. Operating margins increased from 27.5% to 28.4%.

Underlying revenues were up 7.8% and underlying adjusted operating profits were 9.2% higher in H125, reflecting "further strong growth" in Live B2B Events and Academic Markets.

The FTSE 100-listed firm also said roughly £3.1bn, representing 80% of 2025 revenue, was committed or visible through subscriptions, forward bookings and contracts, up from £2.7bn at H124. Informa added that a further £500.0m of revenue was booked and committed for 2026, up approximately 15% year-on-year.

As a result, group underlying revenue growth guidance increased from 5% to 6%, including 8% in Informa's Live B2B Events unit. Reported revenue guidance was maintained at more than £4.0bn, while adjusted earnings growth guidance increased to more than 10%, despite further weakening of the US dollar.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.